Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

McKesson
UBS
Novartis
McKinsey
Colorcon
Federal Trade Commission
Harvard Business School
Fish and Richardson
Chinese Patent Office
Express Scripts

Generated: October 20, 2017

DrugPatentWatch Database Preview

INDIUM IN-111 PENTETREOTIDE KIT - Generic Drug Details

« Back to Dashboard

What are the generic drug sources for indium in-111 pentetreotide kit and what is the scope of indium in-111 pentetreotide kit freedom to operate?

Indium in-111 pentetreotide kit
is the generic ingredient in one branded drug marketed by Mallinkrodt Nuclear and is included in one NDA. There is one patent protecting this compound. Additional information is available in the individual branded drug profile pages.

Indium in-111 pentetreotide kit has twelve patent family members in eight countries.

There are twenty-three drug master file entries for indium in-111 pentetreotide kit. One supplier is listed for this compound.

Summary for Generic Name: INDIUM IN-111 PENTETREOTIDE KIT

US Patents:1
Tradenames:1
Applicants:1
NDAs:1
Drug Master File Entries: see list23
Suppliers / Packagers: see list1
Clinical Trials: see list600
Drug Prices:see low prices
DailyMed Link:INDIUM IN-111 PENTETREOTIDE KIT at DailyMed
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Mallinkrodt Nuclear
OCTREOSCAN
indium in-111 pentetreotide kit
INJECTABLE;INJECTION020314-001Jun 2, 1994RXYesYes► Subscribe► Subscribe ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Orange Book Patents for Generic Ingredient: indium in-111 pentetreotide kit

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Mallinkrodt Nuclear
OCTREOSCAN
indium in-111 pentetreotide kit
INJECTABLE;INJECTION020314-001Jun 2, 1994► Subscribe► Subscribe
Mallinkrodt Nuclear
OCTREOSCAN
indium in-111 pentetreotide kit
INJECTABLE;INJECTION020314-001Jun 2, 1994► Subscribe► Subscribe
Mallinkrodt Nuclear
OCTREOSCAN
indium in-111 pentetreotide kit
INJECTABLE;INJECTION020314-001Jun 2, 1994► Subscribe► Subscribe
Mallinkrodt Nuclear
OCTREOSCAN
indium in-111 pentetreotide kit
INJECTABLE;INJECTION020314-001Jun 2, 1994► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Ingredient: indium in-111 pentetreotide kit

Country Document Number Estimated Expiration
Japan3288055► Subscribe
Germany4104308► Subscribe
Hong Kong43497► Subscribe
United Kingdom2241167► Subscribe
France2658421► Subscribe
United Kingdom9004017► Subscribe
JapanH05124979► Subscribe
United Kingdom9103344► Subscribe
Belgium1004645► Subscribe
Italy1244496► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Express Scripts
Cantor Fitzgerald
Cerilliant
Deloitte
US Army
Medtronic
UBS
Julphar
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot